Trial Profile
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Acronyms RESTORE-1
- Sponsors Neurocrine Biosciences; Voyager Therapeutics
- 08 Dec 2023 Phase of this clinical trial has been changed from 2 to 1. Primary endpoint changed so that the trial focus is also changed from TU to AR.
- 08 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Nov 2024.
- 08 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Nov 2024.